Consensus Prothena Corporation plc

Stocks

PRTA

IE00B91XRN20

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-31 EDT			5-day change	1st Jan Change
9.350 ^USD	+0.21%		-0.43%	-2.09%

08-06	Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026.	CI
08-06	Prothena Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Prothena Corporation plc

Evolution of the Target Price: Prothena Corporation plc

Changes in Analyst Recommendations: Prothena Corporation plc

6a45884d733.ygtYBH-EOqBbJgWryyMwc1YNkXTp00sfUzpH3h18bao.u280UTXoe_ptEWrn-2J8EGBL3yGP6wp7Hls3lGo_FJuyPBdhMdcCmSpTRA~7697342fde9c18fbe667393e6fbc7e17

Analysts' recommendations: Prothena Corporation plc

02-20	RBC Raises Price Target on Prothena to $12 From $11, Keeps Sector Perform, Speculative Risk	MT
11-07	RBC Capital Adjusts Prothena Price Target to $11 From $10, Maintains Sector Perform Rating	MT
25-10-01	Prothena's partner Bristol Myers Squibb obtains fast track designation from US FDA for BMS-986446 for treatment of Alzheimer's disease	RE
25-08-05	RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk	MT
25-05-28	BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target	MT
25-05-27	Oppenheimer Downgrades Prothena to Market Perform From Outperform	MT
25-05-27	Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32	MT
25-05-27	Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating	MT
25-05-09	RBC Trims Price Target on Prothena to $18 From $20, Keeps Sector Perform, Speculative Risk	MT
25-02-21	RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk	MT
24-12-20	Chardan Initiates Coverage on Prothena With Buy Rating, $40 Price Target	MT
24-08-14	Oppenheimer Cuts Prothena Price Target to $62 From $66, Outperform Rating Maintained	MT
24-08-09	RBC Cuts Price Target on Prothena to $24 From $28, Keeps Sector Perform, Speculative Risk	MT
24-05-09	RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk	MT
24-02-20	Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating	MT
24-02-16	RBC Trims Price Target on Prothena to $35 From $36, Keeps Sector Perform, Speculative Risk	MT
24-01-25	RBC Cuts Price Target on Prothena to $36 From $43, Calls Initial Data on PRX012 'Anticlimactic,' Keeps Sector Perform, Speculative Risk	MT
23-12-12	Deutsche Bank Initiates Coverage on Prothena With Buy Rating, $62 Price Target	MT
23-11-02	RBC Cuts Price Target on Prothena to $43 From $60, Keeps Sector Perform, Speculative Risk	MT
23-08-04	JMP Securities Adjusts Prothena's Price Target to $83 From $82, Keeps Market Outperform Rating	MT
23-05-08	Cantor Fitzgerald Adjusts Prothena Price Target to $120 From $98, Maintains Overweight Rating	MT
23-05-05	HC Wainwright Adjusts Price Target on Prothena to $90 From $75, Maintains Buy Rating	MT
23-05-05	RBC Boosts Price Target on Prothena to $60 From $55, Maintains Sector Perform, Speculative Risk	MT
23-04-24	SVB Securities Starts Prothena at Outperform With $80 Price Target	MT
23-02-27	Citigroup Adjusts Price Target on Prothena to $72 From $76, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROTHENA CORPORATION PLC					+129.37%
	WUXI APPTEC CO., LTD.					+16.85%
	ARGENX SE					+9.86%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.81%
	INSMED INCORPORATED					+68.87%
	BIONTECH SE					+17.86%
	PHARMAESSENTIA CORPORATION					-13.15%
	GENMAB A/S					+12.58%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+20.2%
	EXELIXIS, INC.					-2.66%
	Average					+27.06%
	Weighted average by Cap.					+16.53%